The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
In the second part of this two-video series, Guillermo Garcia-Manero, MD, continues his discussion of lower-risk myelodysplastic syndromes with SOHO young investigators during SOHO 2026.
A Biologics License Application was submitted to the US Food and Drug Administration for the BCMA-directed, 2nd-generation bispecific antibody etentamig for the treatment of relapsed or refractory multiple myeloma, as reported by the drug’s manufacturer, AbbVie.
Ententamig is a second-generation bispecific T-cell engager targeting CD3 and B-cell maturation antigen with a low-affinity CD3 binding domain, potentially reducing rates of cytokine release syndrome (CRS) and infection, wrote the study’s authors, led by Peter Voorhees, MD, of Atrium health Levine Cancer Institute in Charlotte, North Carolina.
The European Medicines Agency Committee for Medicinal Products for Human Use has recommended an indication extension for talquetamab (TALVEY) plus daratumumab with or without pomalidomide; the recommendation covers adults with relapsed or refractory multiple myeloma who have received at least one prior therapy, according to a press release from the drug’s manufacturer, Johnson and Johnson.
The analysis, led by Adam D. Cohen, MD, of University of Pennsylvania in Philadelphia, reviewed 20 patients from Cohort A of the CARTITUDE-2 trial that rolled over to the 15-year follow-up study, CARTinue.
The study’s authors, led by Marin Schrappe, MD, of Christian Albrechts University Kiel and University Hospital Schleswig-Holstein in Germany, enrolled pediatric patients with high-risk B-ALL to receive two cycles of either blinatumomab or control chemotherapy after consolidation therapy. The primary end point was EFS based on a time-to-event analysis.
SOHO Insider is the official media platform of the Society of Hematologic Oncology. The SOHO Insider Editorial Board is comprised of leading hematologists. Learn more about our editorial board and SOHO Insider platforms.
To access the SOHO Career Center click the following link.
